On April 8, 1997, after buying the remaining % of Roussel-Uclaf stock in early 1997,  Hoechst AG ( US$30 (equivalent to $ in 2016) billion annual revenue) announced the end of its manufacture and sale of Mifegyne ( US$ (equivalent to $ in 2016) million annual revenue) and the transfer of all rights for medical uses of mifepristone outside of the United States to Exelgyn ., a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz.  In 1999, Exelgyn won approval of Mifegyne in 11 additional countries, and in 28 more countries over the following decade. 
In 2010, the Natural Resources Defense Council forced the FDA to review triclosan after suing them for their inaction. Because the FDA prohibited hexachlorophene , a compound similar to triclosan, Halden and others argued that the FDA should also ban triclosan.  On December 17, 2013, the FDA issued a draft rule revoking the Generally recognized as safe status of triclosan as an ingredient in hand wash products, citing the need for additional studies of its potential endrocrine and developmental effects; impact on bacterial resistance; and carcinogenic potential. 
Do not consider WebMD User-generated content as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.